Yang Li
李阳
Yang Li is a biotech entrepreneur and the co-founder and chairman of ReviR Therapeutics, an AI-driven RNA therapeutics company. As described in 5Y Capital's coverage, he has led ReviR since its early days — the firm was already in his hands by early 2022, when he spoke of assembling talent across AI, RNA biology, and high-throughput screening to tackle unmet clinical needs . By mid-2024, he was steering the company through a $30 million Series A as it moved from platform-building toward clinical trials, with a focus on oral gene therapies that regulate RNA to treat neurological diseases . The company first appeared in 5Y Capital's portfolio discussions by April 2021, with Yang already positioned as its chairman .
elsewhere's corpus does not cover his background prior to ReviR, nor any other affiliations.
AI-generated — may contain errors, please verify.
Coverage
What's Still Missing When AI Enters the Physical World? A Look Back at the Attention WAIC Special Session
After talking with six guests, there's still no standard answer for how "done" world models are
5Y News | 5Y Capital Portfolio Company ReviR Therapeutics Raises $30 Million in Series A Funding
Continuing to advance "oral gene therapy" through AI+RNA.
5Y News | AI+RNA Startup ReviR Therapeutics Closes Tens of Millions of Dollars in Pre-A Round
Using AI algorithms and gene technology to drive targeted RNA drug development.
5Y Talk | How Can Computing and AI Break Through the Traditional Paradigm of Drug Discovery?
Entering the Game, Direction, and the Future.
